The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Immuno-Oncology Drugs Market During The Forecast Period?
The immuno-oncology drugs market size has experienced rapid growth in recent years. It is forecast to grow from $120.37 billion in 2025 to $136.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. This historical expansion can be attributed to the limited availability of immuno-oncology drugs, a reliance on conventional chemotherapy, the increasing prevalence of cancers such as melanoma and lung cancer, growing oncology-focused research initiatives, and early regulatory approvals for monoclonal antibodies.
The immuno-oncology drugs market is expected to experience significant expansion in the coming years. It is projected to reach $226.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This growth in the forecast period can be attributed to the development of bispecific antibodies and oncolytic virus therapies, an expansion of personalized immunotherapy solutions, increasing investment in adoptive cell transfer therapies, rising healthcare expenditure on cancer treatment, and the integration of digital platforms for patient monitoring and clinical trials. Major trends anticipated during this period include the increasing adoption of immune checkpoint inhibitors across multiple cancer types, growth in the development of cancer vaccines and adoptive cell therapies, a heightened focus on personalized immuno-oncology treatments, the expansion of hospital and ambulatory surgical center-based immunotherapy programs, and an uptick in clinical trials and research activities related to monoclonal antibodies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp
Which Primary Drivers Are Impacting The Immuno-Oncology Drugs Market Growth?
The growing occurrence of cancer cases is projected to drive the expansion of the immuno-oncology drugs market. Cancer is characterized by the uncontrolled growth of abnormal cells, potentially spreading throughout the body and impairing normal functions. The increase in cancer cases is attributed to factors such as demographic aging, evolving lifestyles, and improved detection methodologies. Immuno-oncology drugs facilitate this by stimulating the body’s immune system to target and eliminate cancer cells, thereby providing more effective and precise treatment options. For instance, in 2023, Cancer Australia, an Australia-based government agency, estimated that 164,694 new cancer cases were diagnosed and 51,269 deaths occurred, with prostate, breast, melanoma, colorectal, and lung cancers being the most prevalent, while rare cancers represented about one-third of diagnoses and 42% of deaths. Consequently, the rising incidence of cancer cases is fueling the growth of the immuno-oncology drugs market.
Which Segment Classifications Are Used In The Immuno-Oncology Drugs Market Segment Analysis?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
Which Trends Are Shaping The Immuno-Oncology Drugs Market?
Key players within the immuno-oncology drugs market are forming alliances to create and market a new checkpoint antibody, aiming to improve the efficacy of cancer therapies. These strategic partnerships drive innovation by facilitating the sharing of knowledge across various disciplines, which in turn accelerates the creation of combination therapies, customized treatments, and new drug administration methods. An example of this is the collaboration in March 2023 between BioNTech SE, a company headquartered in Germany, and OncoC4 Inc, a pharmaceutical firm based in the US. They teamed up to jointly develop and commercialize a checkpoint antibody, specifically the anti-CTLA-4 monoclonal antibody candidate identified as ONC-392. The objective of this joint venture is to broaden cancer treatment alternatives for various solid tumor types.
Which Firms Are Contributing To The Immuno-Oncology Drugs Market Ecosystem?
Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.
Get The Full Immuno-Oncology Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report
Which Region Holds The Highest Market Share In The Immuno-Oncology Drugs Market?
North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Immuno-Oncology Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report
Browse Through More Reports Similar to the Global Immuno-Oncology Drugs Market 2026, By The Business Research Company
Veterinary Laboratory Testing Services Market Report 2026
Dermatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model